Abstract 1931: A potential antitumor herb medicine, Corilagin, inhibits ovarian cancer cell growth by blockage of TGF-β/AKT/ERK signaling pathways

Recently, we have identified that Corilagin is a major anti-tumor active component extracted from a well-known hepatoprotective and antiviral medicinal herb, Phyllanthus niruri L. Corilagin distinctly inhibited the growth of ovarian cancer cell lines SKOv3ip, Hey and HO-8910PM, with IC50s less than 20µg/ml, while displayed the low toxicity against normal ovarian surface epithelium (OSE), with IC50s around 100µg/ml. Corilagin induced cell cycle arrest at G2 stage and enhanced apoptosis in Hey cancer cells. To explore its anti-tumor activity in vivo, Corilagin was delivered intra-peritoneally to the mice bearing SKOv3ip xenograft. Although no statistical difference observed on mice weight between untreated and Corilagin treated groups, xenograft tumor growth was significantly restarted by 15µg/mL of Corilagin treated group comparing to untreated control group (p Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1931. doi:1538-7445.AM2012-1931